62887Web Connected Platform for Capturing COVID-19 Rapid Test Data to Support Decision-Makers in Real-TimeClosedFeasibility StudiesInnovate UKAccurate, real-time data is essential in the ongoing fight against the coronavirus. Diagnostic testing is being held up as the key to understanding and slowing the spread of the virus. The approach has already had an impact in some countries during this outbreak and was endorsed by the WHO director-general, who urged countries to ramp up testing activity. Similar to governments across the globe, the UK Government is buying huge quantities of rapid tests. Just like police drug tests, they give quick results and are highly accurate, affordable and portable, making them the obvious choice for mass population testing. They are much more fit for this purpose unlike the current frontline standard - the laboratory PCR test - which may be accurate but doesn't offer the turnaround time needed to combat a pandemic. The latest generation of rapid diagnostic tests generate data which reveals valuable information about how the virus is spreading and allows authorities to predict future spread. Using this data, governments can take informed steps to action targeted interventions and protect public health. Rapid tests provide accurate, lab-grade results at the point of testing. However, results can't always be read by the naked eye, so interpreting them is done either via portable, optical reader devices or smartphone readers, which utilise the phone's camera technology. This also mitigates the issues with misinterpretation. **However, the data these diagnostic devices generate is not being captured and used to its full advantage.** Our project is addressing this gap by providing the web platform and technology needed to connect these devices to the internet. Data is captured at the point of testing, stored and aggregated in the cloud where algorithms can be introduced to analyse it. It is instantly visualised on dashboards for decision-makers in real-time. Additional data such as gender, age, underlying health conditions, blood type, and location will be collected, giving richer insight into epidemiology. Geo-tagged results and data trends will be made available on heat maps in the dashboard. This will allow the NHS, public health bodies and other stakeholders to monitor emerging hot spots, enhance response times and allocate resources. This is a completely novel approach. There are several projects around data capture but none of the proposed solutions integrate with an accurate, rapid diagnostic test. Our solution will not only help contain the coronavirus but ultimately eradicate it- and when fully deployed - prevent future waves of the pandemic. The proposed extensions and added value are: 1. To develop an additional API (application programming interface) to enable interoperability between our system TRANSFORM and various electronic patient data systems in the UK and the US. In the UK, NHS Digital is moving towards the adoption of interoperable Electronic Patient Record (EPR) system to facilitate better patient data access. Data is collected from systems such as TRANSFORM, so smooth integration and communication between the systems is essential. This represents added value for both the UK public and UK Public Health agencies because the datasets will be much more comprehensive, including additional layers of accurate test, subject, symptom, location and environmental data. This is pretty much all the data public health bodies need in order to make informed decisions fast. 2. To extend the functionality of TRANSFORM to incorporate additional comorbidity coding to the records generated for each subject (patient) who using the system to collect data from the rapid lateral flow tests. The comorbidity coding is achieved using internationally recognised standards: SNOMED, and LOINC. These standards are universal and recognised in UK/EU/USA and are used to provide an interoperable medical condition and co-morbidity metadata set for each patient. Both these extended deliverables will enhance the functionality and value of our project in the mid term.